Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ANIK · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortAnika Therapeutics, Inc. is loss-making.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -9.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -9.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -7.3% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.72× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 6.68 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.9% | 35/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 13.8% | 60/100 |
| Operating margin volatility | 5.3% | 61/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -0.3% | 15/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 148 | 114 | 121 | 120 | 113 |
| Cost of revenue | 65 | 41 | 38 | 44 | 49 |
| Gross profit | 83 | 73 | 83 | 76 | 64 |
| Research & development | 27 | 18 | 22 | 26 | 26 |
| Selling, general & admin | 74 | 51 | 60 | 56 | 49 |
| Operating income | 2.6 | 3.7 | 0.8 | (5.1) | (11) |
| Pre-tax income | 2.4 | 4.3 | 3.2 | (2.8) | (9.3) |
| Income tax | (1.7) | 2.1 | 6.6 | 6.1 | 0.7 |
| Net income | 4.1 | (15) | (83) | (56) | (11) |
| Diluted EPS | $0.28 | −$1.02 | −$5.64 | −$3.83 | −$0.76 |
| Diluted shares (millions) | 15 | 15 | 15 | 15 | 14 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of Anika Therapeutics, Inc. are included in the Investor plan. Try free for 7 days →
6.68 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 29, 2026